Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging ...
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
-
Number of Employees:
25-100
-
Annual Revenue:
$1-10 Million